CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CBLL filed a Rule 144 resale notice listing 4,560 shares of common stock to be sold on 03/03/2026. The filing also lists recent officer sales by David J. Foehr, including 5,265 shares on 12/03/2025 for $88,609.95, 5,556 shares on 01/05/2026 for $125,565.60, 5,556 shares on 02/03/2026 for $111,120.00, 569 shares on 02/23/2026 for $11,263.07, and 781 shares on 02/24/2026 for $15,604.38.
Rebecca B. Robertson reported sales of common stock on a Form 144. The record shows a sale of 5,000 shares on 12/08/2025 for $100,000 and a sale of 2,500 shares on 01/02/2026 for $54,725.
The filing also lists 827 shares associated with restricted stock vesting on 03/01/2026 and shows Fidelity Brokerage Services LLC as a broker of record.
Raymond Woo filed a Form 144 reporting proposed and recent sales of Common stock. The notice lists proposed sales of 9,640 and 1,472 shares dated 03/02/2026, and reports recent sales of 11,112 shares on 01/02/2026, 11,112 shares on 02/02/2026, and 705 shares on 02/23/2026. The entries include cash amounts tied to those past sales.
Ceribell, Inc. senior vice president of finance David Foehr sold 1,350 shares of common stock in open-market transactions. The sales involved 781 shares at an average price of $19.98 on February 24, 2026 and 569 shares at $19.79 on February 23, 2026.
According to the disclosure, these shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these sales, Foehr directly owned 17,550 common shares.
Ceribell, Inc. Chief Revenue Officer Joseph S. Manni reported an open-market sale of 768 shares of common stock on February 23, 2026 at $19.79 per share. According to the notes, these shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, he directly owned 26,933 shares, which includes 300 shares acquired under the company’s Employee Stock Purchase Plan on January 30, 2026.
Ceribell, Inc. Chief Technology Officer Raymond Woo reported an open-market sale of 705 shares of common stock at $19.79 per share. According to the disclosure, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. After this transaction, Woo directly holds 166,912 shares of Ceribell common stock.
Ceribell, Inc. Chief Financial Officer Scott Blumberg reported an open-market sale of 808 shares of common stock on February 23, 2026 at a price of $19.79 per share. The sale was made to cover tax withholding obligations related to vesting restricted stock units. Following this transaction, he directly holds 118,334 shares, which includes 300 shares acquired under Ceribell's Employee Stock Purchase Plan on January 30, 2026.
Ceribell, Inc. President and CEO Chao Xingjuan reported an open-market sale of 2,084 shares of common stock on February 23, 2026 at $19.79 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units.
After this transaction, she directly owned 725,164 common shares. The filing also notes an indirect holding of 369,088 shares through the ACP 2021 Trust, where she is a co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership beyond her pecuniary interest.
CeriBell, Inc. is a medical technology company focused on point-of-care EEG for critically ill patients, using AI-powered algorithms to detect seizures, delirium and other serious neurological conditions. Its Ceribell System combines disposable headbands or headcaps, a pocket-sized recorder and a cloud portal for real-time monitoring.
As of December 31, 2025, the system had been adopted by more than 600 U.S. hospitals, targeting a U.S. addressable market it estimates at over $3.5 billion when including seizures and delirium. In 2025 CeriBell generated $89.1 million in revenue, up from $65.4 million in 2024, with a gross margin of 88% and a net loss of $53.4 million.
Growth is supported by expanding clinical indications: FDA 510(k) clearance for its Clarity algorithm to diagnose electrographic status epilepticus in adults and for delirium monitoring, plus Breakthrough Device Designation for an in‑development large vessel occlusion stroke detection solution. The company relies on recurring revenue from single-use Wearables and subscriptions to its software and hardware platform.
Ceribell, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining loss-making. Fourth quarter revenue rose 34% to $24.8 million, with product revenue up 33% and subscription revenue up 37%. Gross margin was a high 87%, but operating expenses increased 24% to $36.2 million, leading to a net loss of $13.5 million, or $0.36 per share.
For full year 2025, revenue grew 36% to $89.1 million, driven by both product and subscription sales. Gross profit reached $78.3 million with an improved gross margin of 88%, but operating expenses rose 42% to $136.7 million, resulting in a net loss of $53.4 million, or $1.46 per share. Ceribell ended the year with $159.3 million in cash, cash equivalents, and marketable securities and 647 active accounts.
The company highlighted multiple regulatory milestones, including two FDA 510(k) clearances and an FDA Breakthrough Device Designation, and guided 2026 revenue to $111–115 million, implying about 25–29% growth over 2025.